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Lymphoepithelioma-like carcinoma (LELC) is an aggressive tumor that rarely affects the prostate. Few
cases are reported in the literature. We present a case report, pathologic description and review of the
literature.
 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Lymphoepithelioma is an undifferentiated malignant carcinoma
linked to Epstein-Barr virus and well-described in the head and
neck literature.1 Tumors with similar histologic features and arising
from other organ systems are referred to as lymphoepithelioma-
like carcinomas (LELC). LELC may affect other sites including
salivary glands, thymus, lung, skin, stomach, breast and the geni-
tourinary tract.2 In the genitourinary tract, LELC most commonly
affects the urinary bladder and prostatic involvement is rare.3,4Case report
A 77 year old male with history of tobacco use, biopsy-
conﬁrmed retroperitoneal ﬁbrosis and dyslipidemia presented to
primary care with dysuria and gross hematuria for 6 weeks. He was
treated with antibiotics followed by an alpha blocker with no
improvement. No digital rectal exam was performed prior to urol-
ogy referral. A computed tomography (CT) scan of the abdomen and
pelvis without oral or intravenous contrast 6 months prior revealed
an atrophic left kidney, retroperitoneal soft tissue surrounding the
aorta and non-speciﬁc scattered subcentimeter mesenteric lymph
nodes and an enlarged prostate. His prostate speciﬁc antigen (PSA)
rose from 3.73 ng/mL to 4.5 ng/mL over 8 months.
The patient was referred to urology and digital rectal exam
revealed a non-tender, asymmetrical, ﬁrm, nodular, large prostate.þ1 570 271 6955.
Inc. This is an open access article uHe underwent a standard 12 core transrectal ultrasound-guided
prostate biopsy which demonstrated large volume LELC in the left
base, left mid and left lateral apex; additionally, 5% Gleason 3 þ 3
adenocarcinoma was identiﬁed in the right lateral base.
On pathologic examination, the tumor cells had irregular
vesicular nuclei, prominent nucleoli and indistinct cytoplasmic
borders with high nuclear/cytoplasmic ratio (Fig. 1). Immunohis-
tochemistry showed tumor cells positive for prostatic carcinoma
markers ERG and NKX3.1 (Figs. 2 and 3), epithelial marker CKAE1/3
and negative for prostatic carcinoma markers (PSA, p504S) and
urothelial carcinoma marker (p63 and GATA3). EBV-encoded RNA
(EBRE) was not identiﬁed by chromogenic in situ hybridization
(CISH).
Staging CT of the chest, abdomen and pelvis with intravenous
contrast revealed a 1.5 cm spiculated nodule in the lingula with
non-speciﬁc mediastinal and right hilar adenopathy most likely
consistent with a chronic inﬂammatory process and less likely
metastatic disease. Furthermore, stable pelvic adenopathy and
inﬁltrative changes were visualized in the retroperitoneum
consistent with the patient’s history of retroperitoneal ﬁbrosis.
Bone scan was negative for metastatic disease. The patient was
taken to the operating room with the intent of radical prostatec-
tomy. Intraoperatively, pelvic nodes were enlarged and ﬁrm and
frozen section was benign. The prostate was large, hard and
immobile with extraprostatic tumor involvement of the distal
membranous urethra and anterior rectal wall. In addition, ﬁbrosis
and adherence likely related to patient’s history of retroperitoneal
ﬁbrosis was noted between the posterior aspect of the prostate
and rectum, rendering dissection extremely difﬁcult. Prostatec-
tomy was aborted and patient referred for pelvic external beam
radiation.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Lymphoepithelioma-like carcinoma: solid nests of tumor cells with dense
lymphocytic inﬁltration (hematoxylin and eosin stain; original magniﬁcation 400).
Figure 3. Strong nuclear staining with NKX3.1 in lymphoepithelioma-like carcinoma
(immunohistochemical stain; original magniﬁcation 400).
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lobe centered in the mid gland fat with extension to the apex and
base with gross extracapsular extension and invasion of the neu-
rovascular bundle. He completed a 9 week course of external beam
radiation therapy consisting of 8100 cGy in 45 fractions. He toler-
ated the radiation therapy without immediate side effects and at
last follow up was without symptoms, his PSAwas 0.03 ng/mL, and
CT scan of chest, abdomen and pelvis revealed no evidence of dis-
ease. He will continue on surveillance with physical exam and PSA
every 6 months.Discussion
Lymphoepithelioma is most commonly observed in the naso-
pharynx (i.e. nasopharyngeal carcinoma). The term “lymphoepi-
thelioma” derives from the tumor’s characteristic histologic
appearance, in which large polygonal epithelial cells are often
surrounded by lymphoid cells. An association between nasopha-
ryngeal carcinoma and Epstein-Barr virus has been observed, with
EBV latent genes contributing to alteration in cellular gene expres-
sion and growth. Treatment typically consists of radiotherapy withFigure 2. Strong nuclear staining with ERG in lymphoepithelioma-like carcinoma
(immunohistochemical stain; original magniﬁcation 400).or without chemotherapy.1 The 5 year survival is 72% stage I, 64%
stage II, 62% stage III, and 38% for stage IV.5
LELC of the prostate is a rare, aggressive malignancy with an
overall poor prognosis. Unlike nasopharyngeal disease, there is no
clear associationwith Epstein-Barr virus. Adlakha et al described the
ﬁrst case of LELC of the prostate in a 66 year old man with
obstructive urinary symptoms.4 The patientwas treatedwith radical
prostatectomy and followed for 15 months without complications.
In a cases series of 5 patientswith LELC of the prostate; all presented
with obstructive urinary symptoms and an elevated PSA.3 Themean
age at diagnosis was 76 years and the initial diagnosis was made on
transurethral resection in 3 patients and radical prostatectomy in
the remainder. The mean follow up period was 20.2 months; 1 pa-
tient was lost to follow up and 4 died of disease.
Histologic ﬁndings in the few reported cases of prostatic LELC
include syncytial cell arrangement and vesicular nuclei, absence of
lumen formation, polyclonal lymphoid stroma, and positive
immunoreactivity with PSA and a-methylacyl coenzyme A race-
mase (AMACR) in specimens from radical prostatectomy or tran-
surethral resection of prostate.3 While the presented case was
immunoreactive for PSA and had a histologic pattern characteristic
of LELC, comparison with prior case series is limited by needle bi-
opsy specimen.
In summary, LELC of the prostate is a rare, aggressive malig-
nancy with poor prognosis. An accurate diagnosis is essential as
LELC of prostate tends to arise in the background of adenocarci-
noma. Further research is needed to reﬁne diagnosis and treatment
for this rare, aggressive entity.
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